Innara Health, a Serra Capital I portfolio company, released findings from their recent study on May 2. Innara Health is a commercial stage medical device company developing and selling pulsatile neurostimulation products that address the overwhelming problem of incompetent feeding in premature infants. Innara’s first product, the NTrainer™ System, solves this problem by assessing and treating their dysfunctional oral feeding, accelerating healthy development and enabling them to leave the hospital sooner.
A multi-center randomized control trial has shown that premature infants who were on feeding tubes and who received treatment with Innara Health’s NTrainer System® demonstrated improved transition to independent oral feeding and a reduction in length of stay in the neonatal intensive care unit (NICU). “The study demonstrates the clear benefit of interventional feeding therapy for premature and newborn infant patient populations,” said Dr. Dongli Song, the chief principal investigator of the study. “The NTrainer helped the infants who received treatment safely go home with their families sooner.”
The results of the 210-patient study will be presented at the Pediatric Academic Societies 2016 Meeting April 30-May 3, 2016, in Baltimore.